NextCure (FRA:2US) Net Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is NextCure Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. NextCure's Net Income for the three months ended in Mar. 2024 was €-15.74 Mil. NextCure's Revenue for the three months ended in Mar. 2024 was €0.00 Mil. Therefore, NextCure's net margin for the quarter that ended in Mar. 2024 was 0.00%.

The historical rank and industry rank for NextCure's Net Margin % or its related term are showing as below:

FRA:2US's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -148.36
* Ranked among companies with meaningful Net Margin % only.

NextCure Net Margin % Historical Data

The historical data trend for NextCure's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextCure Net Margin % Chart

NextCure Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

Get a 7-Day Free Trial

-531.57

-163.57

NextCure Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of NextCure's Net Margin %

For the Biotechnology subindustry, NextCure's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NextCure's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NextCure's Net Margin % distribution charts can be found below:

* The bar in red indicates where NextCure's Net Margin % falls into.

NextCure Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

NextCure's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-57.517	/	0
	=	%

NextCure's Net Margin for the quarter that ended in Mar. 2024 is calculated as

Net Margin	=	Net Income (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-15.738	/	0
	=	%

NextCure (FRA:2US) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

NextCure Net Margin % Related Terms

Thank you for viewing the detailed overview of NextCure's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

NextCure (FRA:2US) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCure Inc (FRA:2US) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

NXTC:USA

Address

9000 Virginia Manor Road, Suite 200, Beltsville, MD, USA, 20705

Website

https://www.nextcure.com

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include NC410 a fusion protein of LAIR-2, a naturally occurring soluble version of and decoy protein for LAIR-1 and is designed to block immune suppression mediated by LAIR-1, NC762 a monoclonal antibody that binds specifically to human B7 homolog 4 protein, or B7-H4, a protein expressed on multiple tumor types, and NC525 (LAIR-1 mAb) is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia, or AML, blast cells, and leukemic stem cells, or LSCs.

NextCure (FRA:2US) Headlines

No Headlines